NO20084619L - Legemiddel i form av mikropartikler - Google Patents

Legemiddel i form av mikropartikler

Info

Publication number
NO20084619L
NO20084619L NO20084619A NO20084619A NO20084619L NO 20084619 L NO20084619 L NO 20084619L NO 20084619 A NO20084619 A NO 20084619A NO 20084619 A NO20084619 A NO 20084619A NO 20084619 L NO20084619 L NO 20084619L
Authority
NO
Norway
Prior art keywords
microparticles
drug
carrier material
material particles
inhalation
Prior art date
Application number
NO20084619A
Other languages
English (en)
Norwegian (no)
Inventor
Moshe Flashner-Barak
E Itzhak Lerner
Roud Smit
Richard Van Lamoen
Erwin V Achthoven
Hans Keegstra
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20084619L publication Critical patent/NO20084619L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20084619A 2006-04-03 2008-10-31 Legemiddel i form av mikropartikler NO20084619L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78919706P 2006-04-03 2006-04-03
US85477806P 2006-10-26 2006-10-26
PCT/US2007/008685 WO2007117661A2 (fr) 2006-04-03 2007-04-03 Microparticules médicamenteuses

Publications (1)

Publication Number Publication Date
NO20084619L true NO20084619L (no) 2008-12-16

Family

ID=38581674

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084619A NO20084619L (no) 2006-04-03 2008-10-31 Legemiddel i form av mikropartikler

Country Status (12)

Country Link
US (1) US20080057129A1 (fr)
EP (1) EP2010153A2 (fr)
JP (1) JP2009532489A (fr)
KR (1) KR20080105174A (fr)
BR (1) BRPI0709872A2 (fr)
CA (1) CA2647073A1 (fr)
IL (1) IL194095A0 (fr)
MX (1) MX2008012794A (fr)
NO (1) NO20084619L (fr)
RU (1) RU2008142388A (fr)
TW (1) TW200817047A (fr)
WO (1) WO2007117661A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009064469A1 (fr) * 2007-11-14 2009-05-22 Nektar Therapeutics Administration pulmonaire d'un antibiotique macrolide
WO2009142852A2 (fr) 2008-05-22 2009-11-26 3M Innovative Properties Company Procédé de fabrication de compositions médicamenteuses pulvérulentes coulables
EP2309978B1 (fr) 2008-06-26 2018-12-26 3M Innovative Properties Company Compositions pharmaceutiques de poudre sèche pour une administration pulmonaire et leurs procédés de fabrication
EP2174654B1 (fr) * 2008-10-09 2012-08-22 Bobelium, S.L. Composition micronisée de 2,4,6-triiodophenol
US8168597B2 (en) * 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
KR20110104120A (ko) * 2009-01-26 2011-09-21 테바 파마슈티컬 인더스트리즈 리미티드 극미립자를 이용한 담체 코팅 방법
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
KR20120113267A (ko) * 2010-01-15 2012-10-12 리쎄라 인코오포레이티드 동결건조 케이크 제제
WO2011121425A1 (fr) * 2010-03-31 2011-10-06 Glenmark Pharmaceuticals Limited Composition de poudre pharmaceutique pour inhalation
BR112012028037A2 (pt) 2010-05-03 2016-08-02 Teikoku Pharma Usa Inc formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit
EP2621588A4 (fr) * 2010-09-27 2014-09-03 Microdose Therapeutx Inc Procédés et compositions pour le traitement de maladie en utilisant l'inhalation
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
SG10201604560TA (en) * 2011-04-12 2016-07-28 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
JP5981123B2 (ja) * 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014083026A1 (fr) * 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Inhibiteur de tyrosine kinase de bruton
EP2964199B1 (fr) 2013-03-04 2020-04-22 Besins Healthcare Luxembourg SARL Compositions pharmaceutiques séchées par pulvérisation contenant des nanoparticules d'agent actif
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
MX2017000855A (es) * 2014-07-18 2017-05-01 Allergan Inc Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares.
FR3039990B1 (fr) 2015-08-10 2018-07-06 Rhodia Operations Procede d'encapsulation
WO2017147420A1 (fr) * 2016-02-25 2017-08-31 The University Of Florida Research Foundation, Inc. Procédés et compositions avec des composés de vitamine d pour le traitement de la fibrose kystique et de troubles respiratoires
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
WO2019135812A2 (fr) * 2017-10-12 2019-07-11 Board Of Regents, The University Of Texas System Méthodes et dispositifs pour favoriser la croissance et la régénération nerveuse
US11872240B2 (en) 2018-08-06 2024-01-16 Chander SHEKHAR Antimicrobial formulations comprising vancomycin or tobramycin
EP4304562A1 (fr) * 2021-03-12 2024-01-17 Board of Regents, The University of Texas System Procédés de préparation de poudres sèches à l'aide d'une congélation de film mince à base de suspension

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5429566B2 (fr) * 1974-09-13 1979-09-25
NL8600731A (nl) * 1986-03-21 1987-10-16 Dmv Campina Bv Verbeterde gesproeidroogde lactose en werkwijze ter bereiding ervan.
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
AU747877B2 (en) * 1998-05-27 2002-05-30 Euro-Celtique S.A. Drug delivery system comprising a tightly compacted solid medicament stock
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
US20040043043A1 (en) * 2000-09-20 2004-03-04 Schlyter Jimmy Hirschsprung Preparation of emulsions and concentrates thereof
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
IL160570A0 (en) * 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
GB0201400D0 (en) * 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
EP2087882A1 (fr) * 2002-03-26 2009-08-12 Teva Pharmaceutical Industries Ltd. Microparticules de médicament
CA2489124A1 (fr) * 2002-06-17 2004-12-02 Epigenesis Pharmaceuticals Llc Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes
KR20050056222A (ko) * 2002-09-30 2005-06-14 아쿠스피어 인코포레이티드 흡입용 지속 방출형 다공성 미세입자
WO2004075874A1 (fr) * 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Procede de traitement et de prevention des infections aigues et chroniques des voies aeriennes par pseudomonas aeruginosa au moyen de macrolides pouvant etre inhales
CA2543577A1 (fr) * 2003-11-21 2005-06-16 Galderma Research & Development, S.N.C. Composition pulverisable destinee a administrer des derives de la vitamine d

Also Published As

Publication number Publication date
CA2647073A1 (fr) 2007-10-18
EP2010153A2 (fr) 2009-01-07
RU2008142388A (ru) 2010-05-10
TW200817047A (en) 2008-04-16
JP2009532489A (ja) 2009-09-10
IL194095A0 (en) 2009-08-03
BRPI0709872A2 (pt) 2011-07-26
MX2008012794A (es) 2008-10-15
KR20080105174A (ko) 2008-12-03
WO2007117661A3 (fr) 2008-01-17
WO2007117661A2 (fr) 2007-10-18
US20080057129A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
NO20084619L (no) Legemiddel i form av mikropartikler
CY1122807T1 (el) Συνθεσεις, μεθοδοι και συστηματα για τη χορηγηση δυο ή περισσοτερων δραστικων παραγοντων δια της αναπνευστικης οδου
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
NO20071751L (no) Fremgangsmater og kit for levering av legemidler ved nebulisering
WO2015054124A3 (fr) Inhalateur de poudre sèche
WO2007070851A3 (fr) Procedes d'elaboration de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
WO2007149406A3 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
CY1106269T1 (el) Σωματιδια σκονης με λεια επιφανεια για χρηση σε θepαπεια με εισπνοη
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
TW200640908A (en) Chemical compounds
BR112016026699A8 (pt) uso de amicacina ou de um sal farmaceuticamente aceitável desta
WO2006086107A3 (fr) Methodes et compositions destinees a reduire l'accumulation d'insuline inhalable dans les poumons
BRPI0809011A8 (pt) composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única
MY141025A (en) Dose forms
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
WO2007131168A3 (fr) Inhibiteurs de la sécrétion d'antigènes du virus de l'hépatite b destinés au traitement d'un virus de l'hépatite chronique
BRPI0607168A2 (pt) terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
NO20051414L (no) Fremgangsmate for fremstilling av torrpulverinhaleringssammensetninger
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
WO2009029622A3 (fr) Médicaments antiviraux pour le traitement d'une infection par arénavirus
NO20090968L (no) Fremgangsmater for a behandle multippel myeloma ved anvendelse av kombinasjonsterapier basert pa anti-CS1 antistoffer
WO2009032034A3 (fr) Forme posologique de picoplatine stabilisée
MX2013013503A (es) Composiciones de vancomicina en polvo seco y metodos asociados.
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application